Research
Hormonal
Multi-agonists targeting GLP-1R along with other receptors (GIPR, GCGR) demonstrate superior weight loss and glycemic control compared to single GLP-1R agonists.
Newer 'multi-agonist' diabetes and obesity drugs (like Tirzepatide) target multiple hormone receptors simultaneously. This approach often leads to greater weight loss and better blood sugar control than older single-target GLP-1 drugs. They are taken as weekly injections and are approved for both Type 2 Diabetes and Obesity.
StrongSupportsHIGH confidence
Tirzepatide, the first dual agonist for the treatment of T2DM and obesity targeting GIPR and GLP-1R... showed non-inferior treatment in glycemic control and superior behavior in weight loss than 1 mg semaglutide.
Why this rating
Based on clinical trial data for approved drugs like Tirzepatide.
Source
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wenwei Wan et al. · Molecules · 2023
narrative_reviewCited 37×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →